Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 24Melanoma 19Squamous Cell Carcinoma of Head and Neck 18Colorectal Neoplasms 16Urinary Bladder Neoplasms 11Breast Neoplasms 11Lung Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Carcinoma, Renal Cell 9Neoplasms 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Neoplasm Metastasis 5Mesothelioma, Malignant 5Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Mesothelioma 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3

Interventions

Paclitaxel 2tremelimumab 1pegfilgrastim 1durvalumab 1Taxes 1Sunitinib 1Mental Status and Dementia Tests 1Lapatinib 1Imatinib Mesylate 1Ifosfamide 1Darbepoetin alfa 1Cisplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dysgerminoma × tremelimumab × Clear all
NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡